One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Acknowledgment of Reviewers, 2022.
doi : 10.1200/JCO.22.01714
Volume 40(31) pgs. 3555-3671 November 1, 2022
Lorlatinib in Frontline Therapy for ALK+ Advanced Non-Small-Cell Lung Cancer: Still a Matter of Debate?.
Perol, Maurice MD 1,; Swalduz, Aurelie MD 1
doi : 10.1200/JCO.22.00859
The Potential of Cancer Care Settings to Address Food Insecurity.
Hastert, Theresa A. PhD 1,2,
doi : 10.1200/JCO.22.01109
Management of Metastatic Hormone-Sensitive Prostate Cancer: Is Docetaxel Needed?.
Kartolo, Adi MD 1; Tannock, Ian F. MD, PhD, DSc 2; Vera Badillo, Francisco E. MD, MSc 1,
doi : 10.1200/JCO.22.00705
A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen x CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma.
D'Souza, Anita MD 1,; Shah, Nina MD 2,; Rodriguez, Cesar MD 3; Voorhees, Peter M. MD 4,; Weisel, Katja MD 5,; Bueno, Orlando F. MD, PhD 6,; Pothacamury, Rajvineeth K. MD 6,; Freise, Kevin J. PhD 6,; Yue, Susan MD 6,; Ross, Jeremy A. PhD 6,; Polepally, Akshanth R. PhD 6,; Talati, Chetasi MD 6,; Lee, Shane MS 6,; Jin, Ziyi MS 6,; Buelow, Ben MD, PhD 7,; Vij, Ravi MD 8,; Kumar, Shaji MD 9,
doi : 10.1200/JCO.22.01504
AB PURPOSE: ABBV-383, a B-cell maturation antigen x CD3 T-cell engaging bispecific antibody, has demonstrated promising results in an ongoing first-in-human phase I study (ClinicalTrials.gov identifier: NCT03933735) in patients with relapsed/refractory multiple myeloma (RRMM). Herein, we report safety and efficacy outcomes of this phase I dose escalation/expansion study.
Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated EGFR.
Miyauchi, Eisaku MD, PhD 1,; Morita, Satoshi PhD 2,; Nakamura, Atsushi MD, PhD 3,; Hosomi, Yukio MD, PhD 4,; Watanabe, Kana MD 5; Ikeda, Satoshi MD 6,; Seike, Masahiro MD, PhD 7,; Fujita, Yuka MD, PhD 8,; Minato, Koichi MD 9,; Ko, Ryo MD, PhD 10,; Harada, Toshiyuki MD, PhD 11; Hagiwara, Koichi MD, PhD 12,; Kobayashi, Kunihiko MD, PhD 13,; Nukiwa, Toshihiro MD, PhD 14,; Inoue, Akira MD, PhD 15,; for the North-East Japan Study Group
doi : 10.1200/JCO.21.02911
AB Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned coprimary or secondary analyses are not yet available.
Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study.
Solomon, Benjamin J. MB, BS, PhD 1,; Bauer, Todd M. MD 2; Ignatius Ou, Sai-Hong MD, PhD 3; Liu, Geoffrey MD 4; Hayashi, Hidetoshi MD, PhD 5; Bearz, Alessandra MD 6; Penkov, Konstantin MD, PhD 7; Wu, Yi-Long MD 8; Arrieta, Oscar MD 9; Jassem, Jacek MD, PhD 10; Calella, Anna M. PhD 11; Peltz, Gerson MD, MPH 12; Polli, Anna BSc 11; Thurm, Holger MD 13; Mok, Tony MD 14
doi : 10.1200/JCO.21.02278
Lorlatinib significantly improved progression-free survival (PFS) versus crizotinib and showed robust intracranial activity in patients with previously untreated advanced ALK-positive non-small-cell lung cancer (NSCLC) in the phase III CROWN trial. Here, we report post hoc efficacy outcomes in patients with and without brain metastases at baseline, and present data on the incidence and management of CNS adverse events (AEs) in CROWN.
Food to Overcome Outcomes Disparities: A Randomized Controlled Trial of Food Insecurity Interventions to Improve Cancer Outcomes.
Gany, Francesca MD, MS 1,2,3,; Melnic, Irina MPH 1; Wu, Minlun MPA 1; Li, Yuelin PhD 1; Finik, Jackie MPH 1; Ramirez, Julia MA 1; Blinder, Victoria MD, MSc 1,2,3; Kemeny, Margaret MD 4; Guevara, Elizabeth MD 5; Hwang, Caroline MD 6; Leng, Jennifer MD, MPH 1,2,3
doi : 10.1200/JCO.21.02400
Food insecurity is prevalent among low-income immigrant and minority patients with cancer. To our knowledge, this randomized controlled trial is the first to prospectively examine the impact on cancer outcomes of food insecurity interventions, with the goal of informing evidence-based interventions to address food insecurity in patients with cancer.
Absolute Risk of Oropharyngeal Cancer After an HPV16-E6 Serology Test and Potential Implications for Screening: Results From the Human Papillomavirus Cancer Cohort Consortium.
Robbins, Hilary A. PhD 1,; Ferreiro-Iglesias, Aida PhD 1; Waterboer, Tim PhD 2; Brenner, Nicole PhD 2; Nygard, Mari MD, PhD 3; Bender, Noemi PhD 2; Schroeder, Lea PhD 2; Hildesheim, Allan PhD 4; Pawlita, Michael PhD 2; D'Souza, Gypsyamber PhD 5; Visvanathan, Kala MD 5; Langseth, Hilde PhD 6,7; Schlecht, Nicolas F. PhD 8,9; Tinker, Lesley F. PhD 10; Agalliu, Ilir MD, ScD 9; Wassertheil-Smoller, Sylvia PhD 9; Ness-Jensen, Eivind MD, PhD 11,12,13; Hveem, Kristian MD, PhD 14; Grioni, Sara BSc 15; Kaaks, Rudolf PhD 16; Sanchez, Maria-Jose MD, PhD 17,18,19,20; Weiderpass, Elisabete MD, PhD 21; Giles, Graham G. PhD 22,23,24; Milne, Roger L. PhD 22,23,24; Cai, Qiuyin MD, PhD 25; Blot, William J. PhD 25; Zheng, Wei MD, PhD 25; Weinstein, Stephanie J. PhD 4; Albanes, Demetrius MD 4; Huang, Wen-Yi PhD 4; Freedman, Neal D. PhD 4; Kreimer, Aimee R. PhD 4; Johansson, Mattias PhD 1; Brennan, Paul PhD 1
doi : 10.1200/JCO.21.01785
Seropositivity for the HPV16-E6 oncoprotein is a promising marker for early detection of oropharyngeal cancer (OPC), but the absolute risk of OPC after a positive or negative test is unknown.
Light-to-Moderate Alcohol Consumption Increases the Risk of Biliary Tract Cancer in Prediabetes and Diabetes, but Not in Normoglycemic Status: A Nationwide Cohort Study.
Park, Joo-Hyun MD, PhD 1,2; Hong, Jung Yong MD, PhD 2,3,; Han, Kyungdo PhD 4; Park, Young Suk MD, PhD 3; Park, Joon Oh MD, PhD 3
doi : 10.1200/JCO.22.00145
To determine whether the dose-response association between alcohol consumption and the risk of biliary tract cancer (BTC), including cholangiocarcinoma (CCA) and gallbladder cancer (GBC), differs according to glycemic status.
Longitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma.
Liquid biopsies in metastatic renal cell carcinoma (mRCC) provide a unique approach to understand the molecular basis of treatment response and resistance. This is particularly important in the context of immunotherapies, which target key immune-tumor interactions. Unlike metastatic tissue biopsies, serial real-time profiling of mRCC is feasible with our noninvasive circulating tumor cell (CTC) approach.
doi : 10.1200/JCO.22.00219
Liquid biopsies in metastatic renal cell carcinoma (mRCC) provide a unique approach to understand the molecular basis of treatment response and resistance. This is particularly important in the context of immunotherapies, which target key immune-tumor interactions. Unlike metastatic tissue biopsies, serial real-time profiling of mRCC is feasible with our noninvasive circulating tumor cell (CTC) approach.
Clinical Validity of 16[alpha]-[18F]Fluoro-17[beta]-Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer.
van Geel, Jasper J.L. MD 1; Boers, Jorianne MD 1; Elias, Sjoerd G. MD, PhD 2; Glaudemans, Andor W.J.M. MD, PhD 3; de Vries, Erik F.J. PhD 3; Hospers, Geke A.P. MD, PhD 1; van Kruchten, Michel MD, PhD 1; Kuip, Evelien J.M. MD, PhD 4; Jager, Agnes MD, PhD 5; Menke-van der Houven van Oordt, Willemien C. MD, PhD 6; van der Vegt, Bert MD, PhD 7; de Vries, Elisabeth G.E. MD, PhD 1; Schroder, Carolina P. MD, PhD 8,; on behalf of the IMPACT-Metastatic Breast Consortium
doi : 10.1200/JCO.22.00400
Determining the estrogen receptor (ER) status is essential in metastatic breast cancer (MBC) management. Whole-body ER imaging with 16[alpha]-[18F]fluoro-17[beta]-estradiol positron emission tomography ([18F]FES-PET) is increasingly used for this purpose. To establish the clinical validity of the [18F]FES-PET, we studied the diagnostic accuracy of qualitative and quantitative [18F]FES-PET assessment to predict ER expression by immunohistochemistry in a metastasis.
Tools for Contralateral Prophylactic Mastectomy Decision Making.
Gail, Mitchell H. MD, PhD 1,; Jatoi, Ismail MD, PhD 2
doi : 10.1200/JCO.21.02782
Women with unilateral breast cancer are increasingly opting for the removal of not only the involved breast, but also for the removal of the opposite uninvolved breast (contralateral prophylactic mastectomy [CPM]), although the risk of contralateral breast cancer (CBC) has decreased in recent years. Models to predict the absolute risk of CBC can help a woman decide whether to undergo CPM.
16[alpha]-[18F]Fluoro-17[beta]-Estradiol Positron Emission Tomography to Measure Regional Estrogen Receptor Expression in Breast Cancer.
Mankoff, David A. MD, PhD 1,2,; Clark, Amy S. MS, MSCE 2,3; Edmonds, Christine E. MD 1; O'Brien, Sophia R. MD 1; Pantel, Austin R. MD, MSTR 1
doi : 10.1200/JCO.22.01055
Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Rapid Recommendation.
Garje, Rohan MD 1; Rumble, R. Bryan MSc 2; Parikh, Rahul A. MBBS, PhD 3
doi : 10.1200/JCO.22.01865
AB ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual. The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options. (C) 2022 American Society of Clinical Oncology
Capecitabine: Still a Standard Option in the Adjuvant Setting of Biliary Tract Cancer?.
Edeline, Julien MD, PhD; Malka, David MD
doi : 10.1200/JCO.22.01213
Reply to J. Edeline et al.
Bridgewater, John MD, PhD; Fletcher, Peter MSc; Primrose, John MD; On behalf of the BILCAP Study Group
doi : 10.1200/JCO.22.01283
The Deep Inspiration Breath-Hold Technique May Be a Win-Win Option for the Treatment of Patients in Node-Positive Early Left-Sided Breast Cancer.
Lu, Yongkai MD; Meng, Du MD; Hui, Beina MD; Yuan, Wei MD; Chen, Ruijuan MD; Li, Yi MD
doi : 10.1200/JCO.22.00931
Patient Selection for Internal Mammary Node Irradiation: Lymphoscintigraphy Can Help.
Hindie, Elif MD, PhD; Groheux, David MD, PhD
doi : 10.1200/JCO.22.01178
Reply to Y. Lu et al and E. Hindie et al.
Thorsen, Lise B.J. MD, PhD; Offersen, Birgitte V. MD, PhD
doi : 10.1200/JCO.22.01302
